Abstract Biomarkers of clinical response to rituximab (RTX) therapy and early predictors of outcome are still under investigation. We report a Xow cytometric immunophenotyping analysis from peripheral blood leukocyte subpopulations of two patients with systemic lupus erythematosus (SLE) associated thrombocytopenia and one patient with rheumatoid arthritis (RA), before and after 6 weeks of treatment with RTX. Our results show a reduced population of CD19 + expressing cells (B cells) after RTX treatment in all three patients. Increased frequency of peripheral regulatory CD4 + CD25 high T cell subset and the CD3
Introduction
Rituximab (RTX) is a monoclonal antibody against CD20 that emerges as an important option of biologic therapy for autoimmune diseases. It was Wrst approved for the treatment of non-Hodgkin lymphomas in 1997 by the Food and Drug Administration, United States. Its application in rheumatology was Wrst evaluated for rheumatoid arthritis (RA) and later for other conditions including systemic lupus erythematosus (SLE), with promising results [1] . CD20 is a non-glycosylated surface membrane phosphoprotein restrictedly expressed in B lymphocytes before plasma cell diVerentiation. Importantly, since plasma cells are not a target for anti-CD20 antibodies, some autoantibodies may persist in serum even after depletion of B cells and clinical improvement of rheumatic diseases [1, 2] .
The exact mechanism of how RTX inXuences the immune responses in autoimmune disorders leading to clinical remission is not known yet. B cell depletion and inhibition of antibody production are unlikely to explain all its therapeutic eVects. RA has a poorly understood pathogenesis but the widely accepted view identiWes rheumatoid factor as an epiphenomenon rather than an autoantibody directly implicated in disease [1] . Furthermore, there is not a clear association between clinical improvement after RTX therapy and B cell depletion, for either RA or SLE patients, or lowering titers of anti-double stranded DNA antibodies (dsDNA), for SLE patients [1] [2] [3] [4] [5] and, thus, research in RTX therapy in autoimmune diseases includes seeking new biomarkers that may predict or measure therapeutic response [6] .
B lymphocytes are not viewed anymore as merely antibody producing cells. They may act as antigen presenting cells (APCs) being the major source of T lymphocyte activation in some models. Moreover, B lymphocytes may produce high amounts of cytokines with immunomodulatory eVects [1, 2, 7] . Decreased T helper cell activation after RTX treatment has been suggested on the basis of lower frequency of costimulatory T cell molecule CD40L positive cells that has been associated with partial and complete remission in patients with lupus nephritis [3, 8] . Interestingly, Xow cytometry analysis of peripheral blood leukocytes after RTX therapy have shown additional eVects on other cell types other than B lymphocytes [2, 3, 7] . After RTX therapy, macrophages produce lower amounts of TNF and exhibit increased expression of CD68, thus developing an APC phenotype as compensatory mechanism for the depletion of APC functioning B cells in RA [9] . Natural killer (NK) and NKT cells are recognized by their cytotoxic and regulatory eVects, implicated in prevention of autoimmunity [10, 11] . For example, NKT cell frequency in peripheral blood is lower in patients with SLE when compared to healthy subjects [12] and decreased values of NKT cell counts are associated with higher levels of anti-dsDNA [13] . T CD4 + CD25 high cells are important natural modulators of self-antigen T cell mediated responses [14] . While such natural regulatory T cells are reduced in patients with SLE [15, 16] , inducible CD4 +
IL10
+ regulatory T cell count increases in SLE patients probably as result of compensatory mechanism [15] .
The aim of this study was to explore the relationship of the peripheral blood regulatory NK, NKT cell subsets and CD4 + CD25
high T cells with clinical response after RTX therapy.
Patients

Case 1 (SLE)
A 21-year-old female patient had 4-year past history of SLE presenting during evolution: malar rash, photosensitivity, arthritis, lymphopenia, nephrotic syndrome and positive antinuclear antibodies. The patient was treated with oral corticosteroids and cyclophosphamide pulses for 2 years with clinical improvement and azathioprine was introduced as maintenance therapy. Later, she presented persistent thrombocytopenia and autoimmune hemolytic anemia refractory to higher dose of azathioprine (150 mg/ day) and 20 mg/day of prednisolone. Therapy with RTX 375 mg/m 2 IV weekly for 4 weeks leads to an increase in platelet count reaching normal Wgure after 1 month. The patient has been followed up with no symptoms and with normal platelet count allowing discontinuation of azathioprine and corticosteroid. She has been out of medication for 17 months.
Case 2 (SLE)
A 42-year-old female patient had 3-year past history of SLE characterized by articular symptoms, photosensitivity, thrombocytopenia, leukopenia and presence of antinuclear antibodies. She had been unsuccessfully treated for 3 years with corticosteroids (oral and pulses), azathioprine, intravenous immunoglobulin and danazol for refractory thrombocytopenia. Treatment with RTX was introduced, following the same protocol as described above, when platelet count reached 25,000/mm 3 . Thrombocytopenia responded well to RTX therapy; however, it recurred 9 months after initial therapy and a new course therapy is ongoing.
Case 3 (RA)
A 48-year-old female patient had 5-year past history of RA and secondary Sjögren's syndrome. Clinical features during evolution were symmetric poliarthritis of large and small joints, anemia, xerophtalmia, intermittent parotid gland enlargement, and positive rheumathoid factor and anticyclic citrullinated peptides (CCP) antibodies. She had been treated with methotrexate, leXunomide, cyclosporine, tacrolimus and sulphasalazine with no clinical improvement. After treatment with RTX, two doses of 1 g IV 2 weeks apart, with prednisone 1 mg/kg per day between doses, there was no clinical control of the disease albeit the patient exhibited rising levels of hemoglobin and lowering levels of erythrocyte sedimentation rate.
Methods
Blood samples
A 1-ml sample of peripheral blood was collected from each patient and normal healthy subject as control using ethylenediaminetetraacetic acid (EDTA). The patients were studied before and after rituximab therapy. Post-treatment evaluation was made after 6 weeks. After the collection, the whole peripheral blood (PB) was analyzed by Xow cytometry. The study was approved by the Ethics Committee of our institution and all patients gave informed consent prior to the collection of blood.
Flow cytometry analysis of peripheral blood
SpeciWc monoclonal antibodies (mAbs) were used with the following conjugated mouse anti-human mAbs in two-and three-color immunocytometric assays: FITC-conjugated mAbs anti-CD3 (HIT3a), PE-conjugated mAbs included anti-CD19 (HIB19), anti-CD25 (IL-2R ) (M-A251) and anti-CD56 (B159), Cy-conjugated mAbs CD4 (RPA-T4) and PE-Cy5 anti-CD16 (3G8). Isotype-matched negativecontrol mouse IgG 1 -FITC, PE or Cy (MOPC-21) mAbs. All mAbs were purchased from Becton-Dickinson (Mountain View, CA, USA).
White blood cell phenotyping was performed according to the manufacturers instructions with the following modiWcations. In 12 £ 75-mm polystyrene tubes 50 l samples of peripheral blood, were added with 50 l of mix containing FACS buVer (HBSS, 10% FCS, 0.01% sodium azide (Sigma-Aldrich), pH 7.2, 5 l of each mAb) and incubated for 30-45 min at 4°C in the dark. Following the incubation, erythrocytes were lysed using 2 ml FACS lysing solution (BD Biosciences Pharmigen, San Diego, CA, USA. 
Results
Depletion of B cell (CD19 + ) occurred in all three patients SLE and RA treated with RTX, 6 weeks after treatment (Fig. 1a) . A slight increase in the percentage of circulating T (CD3 + ) cells in all patients after RTX treatment were observed (Fig. 1b) while only a small rise in T CD4
+ cells in SLE2 patient was detected (Fig. 1c) . A higher population of circulating regulatory CD4 + CD25 high T cells in all treated patients was noted (Fig. 1d) , and comparison between Fig. 1c, d indicates that the raised regulatory T cell population could not be attributed to a higher frequency of total T CD4 + cell count after treatment. The frequency of the total NK cells (CD3 ¡   CD56 +) , were lower in patients either before or after treatment in comparison to controls (Fig. 2a) . The patient with sustained clini- (Fig. 2a) . A decreased population of circulating CD3 ¡ CD16 + CD56 dim NK cell subset was detected in all RTX treated patients (Fig. 2b ). An increase of CD3 ¡
CD16
+ CD56 bright cells was noted in SLE2 patients, but this variation was close to that observed in control untreated subjects (Fig. 3c) while the increase of CD3
dim in the unresponsive RA patient was out of the range of diVerences observed among controls (Fig. 2d) (Fig. 3b) (Fig. 3d) . The most consistent observation was a reduction of all NKT subsets in the patient with sustained clinical response (Fig. 3b, c, d ) albeit a relative percentage of NKT cells was raised in this patient (Fig. 3a) . The SLE2 patient showed a notable rise in circulating NKT3 cells (Fig. 3d) .
Discussion
As expected, RTX promoted depletion of circulating B cell (CD19 + ) in all three patients. In both SLE patients who experienced clinical remission of severe thrombocytopenia and RA patient with no clinical response, the expression of CD19 + B cells in peripheral leukocytes was undetectable 6 weeks after treatment (Fig. 1a) . Although some authors observed a direct relationship between decreased CD19 + B cell and clinical improvement in SLE [2, 19] , not all medical literature on RTX therapy supports this concept [1] suggesting that other not evaluated immune factors may be involved. Indeed, although the B cells depletion occurred after RTX therapy in all three patients of the present study, the clinical response was variable. Both SLE patients present severe thrombocytopenia as the major clinical complication, a situation in which autoantibodies are clearly pathogenic [20] .
In this study, we investigated NK cells subsets based on the cell surface of NK cells expressing lower level of CD56 (CD56 dim CD16 + ), known as a more cytotoxic subset, whereas NK cells (CD56 bright CD16¨) are involved in the regulation, based on the observation that CD56 bright subset is the major source of IFN-cytokines [21] . RTX and other anti-CD20 monoclonal antibodies are known to promote downregulation of CD16, which is the IgG receptor they use to mediate their eVector functions [22] . Therefore, it was important to verify NK cells subsets according to CD16 expression (Fig. 2) . All patients had a relative lower population of circulating NK cells when compared to control subjects. The patient with sustained clinical response had a notable decrease of total NK cell population in peripheral blood, but so did the patient with non responsive RA (Fig. 2a) . The most striking observation was the rise in circulating CD56 bright CD16 ¡ (regulatory NK cells) in the patient with sustained clinical response. More importantly, this elevation occurred in that patient who had higher baseline population of circulating regulatory NK cells. This observation encourages future works focusing on evaluation of regulatory NK cells as a prognostic factor that may predict clinical response after RTX therapy [that could be obtained as early as 6 months (weeks) after initiation of treatment]. In addition, baseline circulating regulatory NK cells must also be explored as a predictor of clinical response. In Fig. 2 , we also show that all patients experienced a decrease in CD3 ¡
CD16
+ CD56 dim cells (Fig. 2b ) and a rise in CD3 ¡ CD16 ¡ CD56 bright (Fig. 2e ). Although these data may suggest a switch from more cytotoxic population to regulatory NK cells, it should be highlighted that such changes may be partially or entirely explained by the downregulation of CD16 promoted by anti-CD20 therapies [22] .
NKT cells were further characterized accordingly to the previous reported classiWcation by Vitelli-Avelar and colleagues [18] 
¡ CD56 + ) cells in indeterminate forms of Chagas disease thus suggesting a potential role of these cells in immunomodulation that may prevent progression to chronic cardiac disease. In the present study, no speciWc change in NKT subsets could be associated with successful treatment (Fig. 3b-d ). An increasing population of circulating NKT3 subset outside the range of variation among controls and other patients was observed in patient SLE2. Curiously, in the SLE with sustained response to RTX, (Fig. 1d) . We were not able to perform FoxP3 analyses in the present study. The transcriptional factor Foxp3 has been used as a better marker of these cells. However, in SLE, disease activity has been found to be inversely correlated better with CD4 + CD25 high T cells than Foxp3 expressing CD4 + T cells. There is a dissociation between CD4 + CD25 high T cells and FoxP3 expression and, in SLE, FoxP3 may be found in CD4 + T cells with low or intermediate expression of CD25 suggesting it may be at least in part a marker of T cell activation [23] . In contrast, FoxP3 has been suggested by other recent papers to be a strong biomarker of response after RTX therapy [7, 24] .
Overall, our results indicate that measurement of circulating B and T lymphocytes, NK and NKT cells subsets, are subject to considerable variations after RTX therapy. It is not currently known to which extent such changes can be attributed to direct eVects of B cell drop or as secondary compensatory mechanism. For instance, macrophage phenotypical changes after RTX infusion are interpreted as a compensatory response to loss of APC function of B cells [9] , while reduced markers of T cell activation are considered a direct response of B cell drop and loss of a source of antigen presentation and cytokines production [3, 8] . Future works on the role of regulatory NK and NKT cells subsets after RTX therapy should have special focus on the association between regulatory CD56 bright NK cell subset and decreased of NKT cell subsets with sustained clinical response.
